Goldman Sachs Group Inc. decreased its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 34.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 373,214 shares of the company's stock after selling 195,795 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.70% of ALX Oncology worth $233,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Almitas Capital LLC lifted its stake in ALX Oncology by 10.6% in the first quarter. Almitas Capital LLC now owns 1,353,141 shares of the company's stock worth $843,000 after acquiring an additional 130,196 shares during the period. Acadian Asset Management LLC raised its holdings in shares of ALX Oncology by 16.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company's stock valued at $806,000 after purchasing an additional 186,883 shares in the last quarter. Bank of America Corp DE lifted its position in shares of ALX Oncology by 492.9% in the 4th quarter. Bank of America Corp DE now owns 1,035,326 shares of the company's stock worth $1,729,000 after purchasing an additional 860,703 shares during the period. Two Sigma Investments LP boosted its stake in shares of ALX Oncology by 6.7% during the fourth quarter. Two Sigma Investments LP now owns 704,131 shares of the company's stock valued at $1,176,000 after purchasing an additional 44,072 shares in the last quarter. Finally, Nuveen LLC purchased a new position in ALX Oncology during the first quarter valued at approximately $103,000. Hedge funds and other institutional investors own 97.97% of the company's stock.
ALX Oncology Trading Up 4.5%
NASDAQ ALXO opened at $1.87 on Monday. ALX Oncology Holdings Inc. has a 52 week low of $0.40 and a 52 week high of $2.05. The company has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.67. The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of 0.11. The firm has a market cap of $100.14 million, a PE ratio of -0.85 and a beta of 1.10.
ALX Oncology (NASDAQ:ALXO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). As a group, sell-side analysts forecast that ALX Oncology Holdings Inc. will post -2.76 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Wall Street Zen lowered ALX Oncology from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, ALX Oncology has an average rating of "Moderate Buy" and an average target price of $3.30.
Get Our Latest Analysis on ALXO
Insiders Place Their Bets
In other ALX Oncology news, CEO Jason Lettmann bought 71,163 shares of the company's stock in a transaction that occurred on Wednesday, September 17th. The shares were purchased at an average cost of $1.08 per share, for a total transaction of $76,856.04. Following the purchase, the chief executive officer directly owned 305,121 shares in the company, valued at $329,530.68. This represents a 30.42% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.00% of the stock is currently owned by company insiders.
ALX Oncology Company Profile
(
Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Read More
Want to see what other hedge funds are holding ALXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ALX Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALX Oncology wasn't on the list.
While ALX Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
